Federal Register of Legislation - Australian Government

Primary content

PB 61 of 2012 Determinations/Health as made
This determination amends the National Health (Price and Special Patient Contribution) Determination 2010 (No. PB 109 of 2010) by removing one brand that is no longer listed and reflecting for plain English reasons the price changes and decreases to five existing brand premiums which took legal effect on 1 August 2012 due to price disclosure reductions.
Administered by: Health
Registered 15 Aug 2012
Tabling HistoryDate
Tabled HR16-Aug-2012
Tabled Senate16-Aug-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 61 of 2012

National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 5)1

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated 9 August 2012

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 5).

            (2)        This Instrument may also be cited as PB 61 of 2012.

2          Commencement

            This Instrument commences on 1 September 2012.

3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

            Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).



Schedule 1     Amendments

 

[1]      Schedule 1, entry for Escitalopram in the form Tablet 10 mg (as oxalate)

(a)           omit from the column headed “Determined Price”:     12.71     substitute:             8.03

(b)           omit from the column headed “Claimed Price”:          16.80     substitute:             10.61

[2]      Schedule 1, entry for Escitalopram in the form Tablet 20 mg (as oxalate)

(a)           omit from the column headed “Determined Price”:     12.79     substitute:             8.10

(b)           omit from the column headed “Claimed Price”:          18.75     substitute:             11.87

[3]      Schedule 1, entry for Meloxicam in the form Tablet 7.5 mg

(a)           omit from the column headed “Determined Price”:     9.60        substitute:             7.33

(b)           omit from the column headed “Claimed Price”:          11.13     substitute:             8.50

[4]      Schedule 1, entry for Meloxicam in the form Tablet 15 mg

(a)           omit from the column headed “Determined Price”:     14.01     substitute:             10.70

(b)           omit from the column headed “Claimed Price”:          15.54     substitute:             11.87

[5]      Schedule 1, entry for Prochlorperazine

(a)           omit from the column headed “Determined Price”:     2.64        substitute:             1.97

(b)           omit from the column headed “Claimed Price”:          5.64        substitute:             4.21

[6]      Schedule 1, entry for Timolol

omit:

 

Eye drops 2.5 mg (as maleate) per mL, 5 mL

Application to the eye

Timoptol

1

4.45

7.09

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.